Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

81 results about "Gene deletion mutation" patented technology

Genetic rearrangement through loss of segments of DNA or RNA, bringing sequences which are normally separated into close proximity.

Universal gene-knockout suicide vector for vibrios and application thereof

InactiveCN105063073AStrong lethal effectWide range of lethal objectsBacteriaHybrid cell preparationAgricultural scienceRestriction enzyme digestion
The invention discloses a universal gene-knockout suicide vector for vibrios and a construction method theroef and provides an application thereof in gene knockout of the vibrios. The universal gene-knockout suicide vector pLP12 is a ring-shaped vector and comprises a PBAD promoter, a repressor protein gene araC, an RP4 transferring initiation site, a chlorampenicol resistant gene, an R6K duplicating initiation site, a multiple-cloning-site area and a lethal gene vmi480; the multiple-cloning-site area at least contains two AhdI restriction enzyme digestion sites; the suicide vector pLP12 is subject to AhdI restriction enzyme digestion to form linearized suicide vector pLP12T. The universal gene-knockout suicide vector adopts entirely-new reverse selection genes vmi480 and is used for replacing the common sacB gene. Foreign fragments carried by the pLP12T are transferred to vibrio cells to be mutated by a jointing mode, under the pressure of antibiotics and reverse selection of products of lethal gene vmi480, first-time homologous recombination and second-time homologous recombination are carried out on the vibrios successively, and finally the mutant strain with deletion of target genes is generated.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI

Brucella molecule marking and virulence deletion attenuated vaccine and preparation method

The invention relates to a Brucella vaccine, in particular to the molecular marker and virulence gene deletion of Brucella vaccine strain. The study uses luciferase modified gene (Luc NF plus) to replace the partial fragment of Bp26 gene of Brucella attenuated vaccine S19 strain by constructing suicide plasmid and adopting the method of targeted homologous recombination (gene targeting), so as to damage the expression of the immunogenicity protein BP26 and construct the gene deletion mutant strain Delta S19-1 of the Brucella Bp26. The BMP18 protein is one of the main virulence factors of Brucella. The invention adopts the same method to exclude the Bmp 18 gene of Delta S19-1, so as to lead the Delta S19-1 not to express the Bmp 18 protein and the Brucella virulence gene deletion mutant strain Delta S19-2 is constructed. The invention solves the problems that the conventional Brucella vaccine can not distinguish between the artificial immunization and the wild bacteria infection of people and animals, the virus is strong and the vaccine is easy to cause the illness of inoculated people and animals. The invention has important significance and practical application value of the monitoring, diagnosis, purification and all the controls of Brucella.
Owner:MILITARY VETERINARY RES INST PLA MILITARY MEDICAL ACAD OF SCI

Detection method and device of gene deletion mutation

The invention discloses a detection method and a detection device of gene deletion mutation. The method comprises the following steps: sequencing exon libraries of a sample to be detected and a comparison sample to acquire sequencing data of the sample to be detected and the comparison sample; respectively calculating sequencing numbers of the sample to be detected and the comparison sample on all windows in a form of dividing the sequencing data into several windows to acquire first sequencing numbers of the sample to be detected and the comparison sample on all the windows; performing homogenization on the first sequencing numbers of the sample to be detected and the comparison sample on all the windows to acquire second sequencing numbers of the sample to be detected and the comparison sample on all windows; dividing the second sequencing number of the sample to be detected on the windows by a median which is acquired from the second sequencing number of the comparison sample on all the windows to acquire a specific value; performing gene deletion mutation in the windows if the specific value is smaller than a set value. According to the method, the median in the comparison sample is used as a comparison standard, and compared with an average value or a standard difference, false positive can be relatively easily differentiated, and the result is relatively accurate.
Owner:BEIJING NOVOGENE TECH CO LTD +1

Genetically engineered attenuated strains of edwardsiella tarda (E.tarda) and application thereof

The invention provides four gene deletion mutants of wild edwardsiella tarda (E.tarda) and derivative strains thereof. The four gene deletion mutants are respectively an E.tarda<deltaEvpC> strain with an EvpC gene losing function and derivative strains thereof, an E.tarda<deltaEvpCdeltaEsrB> strain with an EsrB gene losing function and derivative strains thereof, an E.tarda<deltaEvpCdeltaEsrBdeltaPstB> strain with a PstB gene losing function and derivative strains thereof, and an E.tarda<deltaEvpCdeltaEsrBdeltaPstC> strain with a PstC gene losing function and derivative strains thereof. 1-3 genes such as EvpC, EsrB, PstB, PstC and the like of the attenuated strains have parts causing loss of function or suffer from complete deletion, point mutation, shifting or insertion. Compared with a wild 1101 strain or other virulent strains, the E.tarda<deltaEvpC> strain, the E.tarda<deltaEvpCdeltaEsrB> strain, the E.tarda<deltaEvpCdeltaEsrBdeltaPstB> strain and the E.tarda<deltaEvpCdeltaEsrBdeltaPstC> strain have the advantage that the virulence does not exceed 1/40, 1/400, 1/4000 and 1/4000 of the virulence of the wild E.tarda 1101 strain or other virulent strains. The genetically engineered attenuated strains of E.tarda can be applied as attenuated vaccine strains of E.tarda, genetic engineering vectors or probiotics.
Owner:YELLOW SEA FISHERIES RES INST CHINESE ACAD OF FISHERIES SCI

Bim (Bcl-2 interacting mediator of cell death) gene deletion fluorescent quantitative PCR (polymerase chain reaction) detection primer, probe and detection reagent kit

The invention discloses a Bim (Bcl-2 interacting mediator of cell death) gene deletion fluorescent quantitative PCR (polymerase chain reaction) detection primer, a probe and a detection reagent kit, and belongs to the field of molecular biological detection. The Bim gene deletion fluorescent quantitative PCR detection primer and the probe comprise forward primers 5'-CAACAAACCCATCAGAACAGACAC-3', reverse primers 5'-ACAGCCTCTATGGAGAACAGTGATT-3 and fluorescent probes 5'-FAM-CAGACACTGGAACAAA-MGB-3'. The detection reagent kit comprises the Bim gene deletion fluorescent quantitative PCR detection primer, the probe, premixed liquid of PCR liquid and positive control samples A. The Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit have the advantages that Bim gene deletion mutation can be detected by the aid of the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit, and the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit are simple, convenient and feasible and are high in accuracy and sensitivity and particularly suitable for detecting clinical samples; Bim deletion mutation can be detected, and accordingly the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit can bring convenience for guiding individual treatment on bodies.
Owner:ANHUI DAJIAN MEDICAL TECH CO LTD

Pseudorabies virus gE/gI deletion mutant strain of double expression gC gene and construction and application thereof

The present invention discloses a pseudorabies virus gE/gI deletion mutant strain rPRV-AH-gI-/gE-/gC+ of a double expression gC gene. The pseudorabies virus gE/gI deletion mutant strain is positionedat the position of missing gE/gI gene of recombinant pseudorabies virus rPRV-AH-gI-/gE and is constructed by inserting the gC gene; the nucleotide sequence of the gI/gE gene is shown as SEQ ID NO.1, and the nucleotide sequence of the gC gene is shown as SEQ ID NO.2. Compared with other PRV gene deletion mutant strains, the recombinant pseudorabies virus rPRV-AH-gI/gE-/gC+ inserts the gC gene innovatively by taking the gC gene as one of the main immunogenic proteins of PRV on the basis of the deletion of the gI/gE gene, and induces a body to produce a neutralizing antibody and a cellular immuneresponse. The invention further provides rPRV-AH-gI-/gE-/gC+ inactivated vaccine. The inactivated vaccine has better safety performance, and has better immunogenicity, higher neutralizing antibody level and better immune protection effect compared with an existing PRV mutant strain, can distinguish wild virus infected animals from vaccine immunized animals by an existing PRV gE differentiation diagnosis method, and is expected to be used as a genetic engineering inactivated vaccine for preventing and treating novel epidemic strains of porcine pseudorabies virus.
Owner:SOUTH CHINA AGRI UNIV

Seneca recombinant virus of recombinant A-type foot-and-mouth disease virus VP1 gene, recombinant vaccine strain and preparation method and application of recombinant vaccine strain

ActiveCN111996201AAchieving antigen matchingAchieve immune responsivenessSsRNA viruses positive-senseViral antigen ingredientsAntigenDisease
The invention provides a Seneca recombinant virus of a recombinant A-type foot-and-mouth disease virus VP1 gene, a recombinant vaccine strain and a preparation method and application of the recombinant vaccine strain, and relates to the technical field of gene engineering. The invention provides a Seneca recombinant nucleic acid, the Seneca recombinant virus containing the recombinant nucleic acid, the Seneca recombinant vaccine strain containing the Seneca recombinant virus, and a preparation method and application of the vaccine strain. An SVV/FJ/001 strain is subjected to gene deletion mutation transformation, the VP1 gene of the A-type FMDV is fused into cDNA of the SVV/FJ/001 strain to obtain the Seneca recombinant virus, the recombinant virus can express the fused gene, and an expression product has good reactogenicity; and the obtained vaccine strain is high in antigen productivity, the pathogenicity is remarkably reduced, even no pathogenicity is caused to pigs, the immune response of SVA can be stimulated after animals are immunized by the inactivated vaccine, the immunocompetence aiming at fusion genes can be generated, and the vaccine strain can be used for preventing and controlling Seneca virus and one or more non-Seneca virus.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI

CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene deletion mutation form of cystic fibrosis patients and application of CFTR gene deletion mutation form

The invention discloses a CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene deletion mutation form of cystic fibrosis patients and application of the CFTR gene deletion mutation form. The CFTR gene deletion mutation form is used for protecting proteins including: (a1) a protein obtained by deleting a 508th amino acid residue of a CFTR; and (a2) a protein obtained by deleting 476th to 478th amino acid residues of the CFTR. The CFTR gene deletion mutation form is also used for protecting application of substances for detecting mutation A and/or B to preparation of a kit, wherein the mutation A: 128th to 130th nucleotide deletion of a sequence 3 in a human genome; and the mutation B: 34th to 42nd nucleotide deletion of the sequence 3 in the human genome. Functions of the kit comprise: (c1) evaluation of risks of cystic fibrosis of a person to be detected; (c2) evaluation of the risks of the cystic fibrosis of the person to be detected or offspring of parents to be detected; and (c3) diagnosis or auxiliary diagnosis for judging whether the person to be detected is a patient suffering from the cystic fibrosis or not. The CFTR gene deletion mutation form has an important application value on the diagnosis of the patient suffering from the cystic fibrosis.
Owner:BEIJING CHILDRENS HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products